

Initiatives for Sustainable Growth

June 18, 2026

Our Key Growth Strategies

- **Maximization of product value**
- **Acceleration of global business advancement**
- **Reinforcement of pipelines**

Initiatives to Maximize OPDIVO® Value

Maximization of
product value



- The PD-1 immune checkpoint inhibitor approved first in the world.
- Approved for indications across 14 cancer types in Japan
- Cumulative domestic sales exceeding JPY 1 trillion
- **Driving our growth, funding growth investments, and supporting shareholder returns**



Ongoing Lifecycle Management

New formulation (SC), Combination Therapies (Opdualag),
Indication expansion (rare diseases)

⇒ **Mitigate the impact of the patent cliff (aiming to sustain revenue beyond 2031)**

Strengthening Our Collaboration with Deciphera

Acceleration of global
business advancement



Initial: Standalone

Operations prioritized to expand QINLOCK® and launch ROMVIMZA®

Current: Collaborative

One-team collaboration focused on global development of new projects



Synergies



Accelerating
development
as one-team



Upcoming Product Launches

Reinforcement of pipelines



As of June 18, 2026



US/
EU

QINLOCK®
GIST 4L

ROMVIMZA®
Tenosynovial Giant Cell Tumor

Tirabrutinib
ONO-4059
Primary CNS Lymphoma

QINLOCK®
GIST 2L
KIT Exon 11+17/18

Global Expansion Including Japan

Sapablursen ONO-0530 Polycythemia Vera	ONO-4685 T-cell Lymphoma/ Autoimmune Diseases
ONO-4578 Gastric Cancer 1L (in combination with OPDIVO)	ROMVIMZA® Chronic Graft-versus-host Disease
ONO-2808 Multiple System Atrophy	

Continued Launch of Specialty Products

Japan

OPDIVO
MSI-H Colorectal Cancer 1L

Cenobamate
ONO-2017
Partial-onset Seizures

OPDIVO
Adjuvant Therapy for Hepatocellular Carcinoma

VELEXBRU
Pemphigus 2L

OPDIVO
Subcutaneous Formulation

OPDIVO
Hepatocellular Carcinoma 1L

QINLOCK®
GIST 4L

QINLOCK®
GIST 2L

ROMVIMZA®
Tenosynovial Giant Cell Tumor

BRAFTOVI Capsules
(FOLFOX)
Colorectal Cancer 1L

Povetacicept
ONO-8531
IgA Nephropathy/
Chronic Kidney Disease

Gel-One®
ONO-5532
Osteoarthritis

Cenobamate
ONO-2017
Partial-onset Seizures (pediatric)/ Generalized Tonic-clonic Seizures

Ono Deciphera

ONO-4578 (in-house developed product)

Reinforcement of
pipelines



Target Indication	<p>Gastric cancer (1st-line treatment)</p> <ul style="list-style-type: none">• One of the most prevalent cancers in Japan (approx. 100,000 new cases annually)• Despite the availability of multiple treatment options, the 5-year survival rate remains at approximately 60–70%
Mechanism of Action	<p>Antagonistic effect on prostaglandin receptor(EP4)</p> <ul style="list-style-type: none">• Compound derived from our long-standing prostaglandin research• Potential to enhance efficacy when used in combination with OPDIVO®
Development Status	<p>Phase 2 study (Japan, South Korea, Taiwan) ; results presented at ASCO on June 1 ⇒ The results suggested superior improved outcomes versus standard treatment. A reduction in the risk of death was observed (40% overall; 56% in PD-L1–positive patients)</p>
Outlook	<ul style="list-style-type: none">• Planning to initiate a global Phase 3 study in gastric cancer within the current fiscal year• A global Phase 2 study in colorectal cancer is ongoing• Estimated peak sales: over JPY 100 billion globally (gastric cancer only)

ONO-2808 (in-house developed product)


Reinforcement of
pipelines



Target Indication	Multiple System Atrophy (MSA) <ul style="list-style-type: none">• Progressive neurodegenerative disease (e.g., muscle stiffness, difficulty walking, orthostatic dizziness)• Rare and aggressive intractable disease (average life expectancy: approximately 9–10 years)• No radical treatment currently available
Mechanism of Action	S1P5 receptor agonist <p>Promotes repair of myelin damaged by the disease and may help slow disease progression by inhibiting abnormal accumulation of α-synuclein associated with MSA</p>
Development Status	<p>Interim analysis of Phase 2 study (Japan and the U.S.) showed signals of efficacy and acceptable safety (Results presented at World Parkinson Congress on May 27)</p> <p>⇒ Findings suggested potential slowing in the progression of symptoms affecting activities of daily living and brain atrophy progression (based on MRI assessments)</p>
Outlook	<ul style="list-style-type: none">• Preparations are underway to initiate a Phase 3 study within the current fiscal year• Estimated peak sales: over JPY 100 billion globally• Aiming to provide a new treatment option for patients living with MSA, for which there is currently no radical treatment

Prospect for the Future

※Diagram does not represent actual sales of each product



Growth Drivers

Pipeline	Peak Sales (JPY bn)
Global	
QINLOCK (GIST)	50 – 70
ROMVIMZA (TGCT)	50 – 70
Tirabrutinib (PCNSL)	20 – 30
Sapablursen (PV)	50 – 100
ONO-4578 (GC)	100 -
ONO-2808 (MSA)	100 -
Japan*	
Povetacicept	50 -
Cenobamate	
Gel-One®	

*Total estimated peak sales, including products other than the three listed.

As of June 18, 2026

GIST: Gastrointestinal Stromal Tumor, TGCT: Tenosynovial Giant Cell Tumor, PCNSL: Primary Central Nervous System Lymphoma, PV: Polycythemia Vera, GC: Gastric Cancer, MSA: Multiple System Atrophy



ONO PHARMA

Dedicated to the Fight against Disease and Pain